Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02835833 · ClinicalTrials.gov registry record · Phase 1
Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02835833 is a Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 21 participants.
The verdict
NCT02835833, a Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Angiogenesis, the development of new blood vessels, plays an important role in the disease development and tumor growth in many solid organ malignancies. Bevacizumab was the first anti-angiogenic drug to be approved in solid tumors and has shown advantageous activity with multiple tumor types. However, the responses from Bevacizumab are often transient due to the tumor's manipulative abilities to circumvent the usual pathways to find salvage pathways instead. Nintedanib has demonstrated anti-tumor activity in non-squamous non-small cell lung cancer, colorectal cancer, ovarian cancer, and renal cell cancer. The combination of Bevacizumab and Nintedanib are being proposed to target the tumor's manipulation processes to generate alternate pathways for angiogenesis thus creating a potential benefit to delay tumor growth.
Interventions
- DRUG Bevacizumab
- DRUG Nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-06-09 |
| Est. Completion | 2018-06-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02835833
The ClinicalTrials.gov registry entry for NCT02835833 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT02835833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02835833 about?
NCT02835833 is a clinical study titled "Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors". Angiogenesis, the development of new blood vessels, plays an important role in the disease development and tumor growth in many solid organ malignancies. Bevacizumab was the first anti-angiogenic drug to be approved in solid tumors and has shown advantageous activity with multiple tumor types. Howev...
What is the current status of trial NCT02835833?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2016-06-09. Estimated completion is 2018-06-14.
What interventions are being tested in trial NCT02835833?
The interventions under investigation include: Bevacizumab (DRUG), Nintedanib (DRUG).
Who is sponsoring clinical trial NCT02835833?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.